ERBB2 and breast neoplasm: Moreover, in vitro and in silico evaluations have uncovered ras mutation as a dominant predictor of resistance to PI3K inhibitors in cancers of different origin including breast tumours overexpressing ErbB2 (refs 49, 50, 51).